clinical trial · NCT05503797
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Fore Biotherapeutics·phase2·recruiting·n = 254
Cancer Harboring BRAF AlterationsHGGLGGSolid TumorsPlixorafenib
brief summary
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare BRAF V600-mutated solid tumors, melanoma, thyroid, or recurrent primary CNS tumors.
started
Feb 21, 2023
primary completion
Jun 27, 2026
completion
Dec 28, 2026
last updated
May 18, 2026
official title
A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol